Hypnor

Quick links to important sections

Hypnor

Method of action: Hypnotic

Treatment option: Insomnia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hypnor

Property Description
Active ingredient Zopiclone
Form Oral Tablet
Pharmacological class Nonbenzodiazepine Hypnotic (Z-drug)
Common use Sleep aid / Sleep promoter
Origin Synthetic (Chemically manufactured)

What Type of Medicine is Hypnor (Zopiclone)?

Hypnor is a brand name for the prescription medication containing the active ingredient zopiclone, which is classified as a nonbenzodiazepine hypnotic or "Z-drug." It is a chemically manufactured, synthetic compound that is clinically recognized for its ability to promote sleep in adults.

Zopiclone belongs to the cyclopyrrolone chemical class, which supports its differentiation from older sedative-hypnotics like benzodiazepines. This targeted structure has led to its inclusion on the World Health Organization’s Model List of Essential Medicines, confirming its recognized importance in addressing sleep issues globally.

What is Hypnor's Form and Composition?

Hypnor is supplied as a single-ingredient medication in an oral tablet form, meaning its only active component is zopiclone. As a prescription-only (Rx) medication, it is intended for oral administration and contains inactive components necessary to create the physical pill structure.

Being a single-ingredient drug, its therapeutic effect is reliant on the known properties of zopiclone. Zopiclone's primary function is to cause sleepiness. This focused composition is intended to provide a predictable effect for patients struggling with initiating sleep.

What is the General Purpose of Hypnor?

The general purpose of Hypnor is to act as a sleep promoter or hypnotic, aiding in the initiation and maintenance of sleep. It achieves this by influencing the central nervous system to promote a state of calm and reduced brain activity.

As a targeted sleep aid, Hypnor is designed to help patients who struggle with the primary challenge of falling asleep quickly (sleep onset) and staying asleep without frequent awakenings. Its function is concentrated on bringing about the restful state required for the body and mind to transition into sleep.

Regulatory References

  1. WHO Model Lists of Essential Medicines

What side effects are possible with Hypnor?

Hypnor (zopiclone) is associated with an official spectrum of possible adverse reactions, which are classified by frequency and grouped by the affected body system in regulatory documentation.

Adverse Reaction Classifications

The most frequently reported effects, classified as Common, include the distinct dysgeusia (a bitter or metallic taste), somnolence (daytime sleepiness), and dry mouth. Reactions considered Uncommon involve dizziness, headache, nausea, vomiting, fatigue, agitation, and nightmares. More serious or rare reactions (classified as Rare or Very Rare) include aggression, confusion, hallucinations, and anterograde amnesia (not recalling events that occurred shortly after taking the tablet).

Serious Safety Risks

The regulatory profile highlights serious, though infrequent, risks such as complex sleep behaviors (performing activities like walking, driving, or eating while not fully awake, with subsequent amnesia for the event). Other documented serious adverse events include severe hypersensitivity reactions (e.g., angioedema of the tongue, glottis, or larynx) and respiratory depression, particularly when used in patients with compromised respiratory function or alongside other Central Nervous System (CNS) depressants.

Safety Considerations for Specific Populations

Official labeling defines constraints for certain groups. Older adults have an increased risk of CNS-related effects like dizziness and sedation, which elevates the risk of falls. The medicine is generally contraindicated in patients with severe hepatic impairment and severe respiratory insufficiency. Furthermore, the risk of dependence and withdrawal syndrome (including rebound insomnia) is explicitly documented to increase with the dose and the duration of treatment, particularly with continuous use beyond four weeks.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Official documentation states that an overdose of Hypnor may result in a dose-dependent Central Nervous System (CNS) Depression Cascade. Symptoms can range from initial somnolence and confusion to more severe states, including deep sleep or coma. Documented neurological manifestations include hypotonia (muscle weakness), ataxia (loss of coordination), and general incoordination, often accompanied by hypotension (low blood pressure).

The overdose profile carries a significant risk of life-threatening complications, particularly severe respiratory depression (shallow or difficult breathing). The potential for a fatal outcome is explicitly heightened when Zopiclone is co-ingested with other CNS depressant substances, such as alcohol or opioids.

When Immediate Medical Help is Required

Regulators mandate immediate medical attention for a known or suspected overdose. Individuals must contact emergency services or go to the emergency department straight away.

Immediate medical help is also required for severe, acute reactions, such as angioedema (swelling) involving the larynx or glottis, which is an officially documented risk that may lead to acute airway obstruction.

Management is strictly symptomatic and supportive, focusing on maintaining a clear airway and continuous monitoring of vital signs until stability, as no specific antidote is documented for Zopiclone overdose.

Therapeutic Uses of Hypnor

Quick Facts

  • Primary Use: Management of short-term sleep disturbance.
  • Therapeutic Domain: Helps with difficulties related to sleep initiation and sleep maintenance.
  • Goal of Therapy: Promotes a greater opportunity for sleep.

Hypnor is indicated for the temporary management of insomnia in adults. Insomnia is a common condition characterized by the inability to fall asleep or stay asleep, or a combination of both, resulting in sleep of poor quality or duration.

The use of Hypnor may help individuals who experience difficulty with sleep initiation (falling asleep) or sleep maintenance (staying asleep through the night). The goal of therapy with this medication is to promote a greater opportunity for sleep and support improvements in overall sleep quantity.

As with all prescription medications, Hypnor should be utilized as part of a comprehensive strategy for sleep improvement, which often includes non-pharmacological interventions like cognitive behavioral therapy for insomnia (CBT-I) and healthy sleep habits. Treatment duration should align with clinical recommendations for short-term use.

Eligibility and Restrictions for Use

The eligibility for using Hypnor (zopiclone) is determined by official regulatory criteria, primarily restricting use to adults and strictly prohibiting use in specific populations due to safety concerns documented in labeling.

Contraindications (Who Must Not Use)

Official regulatory documents state that Hypnor is contraindicated and must not be used by patients with:

  • Known hypersensitivity or allergy to zopiclone or its components.
  • Severe impairment of respiratory function, including Severe Sleep Apnoea Syndrome.
  • Myasthenia Gravis (severe muscle weakness).
  • Severe Hepatic Insufficiency (severe liver failure).
  • A history of complex sleep behaviors (such as sleep-driving or sleepwalking) after taking any nonbenzodiazepine hypnotic.

Age and Physiological Restrictions

Population Group Regulatory Eligibility Status
Children and Adolescents (Under 18) Contraindicated / Use Not Established; safety and efficacy are not established in this age group.
Elderly Patients (Aged 65 and over) Restricted Use; requires a lower initial dose due to increased susceptibility to effects like sedation.
Pregnant or Breastfeeding Women Use Not Recommended; potential risks to the infant or fetus are documented in the labeling.

Conditional Use Constraints

Use of Hypnor is permitted under restricted or cautious conditions for populations with certain pre-existing conditions:

  • Patients with mild-to-moderate Hepatic Impairment, Impaired Renal Function, or Chronic Respiratory Insufficiency require a reduced starting dose, as advised by regulatory agencies.
  • Patients with a history of alcohol or drug abuse or those with symptoms of depression should use the medicine with extreme caution, and close monitoring is required.

What should I know about interactions with other medicines?

Hypnor (zopiclone) interaction patterns are officially documented by regulatory authorities, classifying them primarily into pharmacokinetic (PK) and pharmacodynamic (PD) interactions.

PK interactions relate to the drug's metabolism, chiefly through the hepatic CYP3A4 enzyme system. Co-administration with strong CYP3A4 inhibitors, such as ketoconazole or erythromycin, is documented to increase zopiclone plasma concentrations and overall systemic exposure. Conversely, substances that induce CYP3A4 activity, including rifampicin and the herbal product St. John's Wort, are documented to decrease zopiclone exposure, which may reduce its intended hypnotic effect.

PD interactions involve substances that cause an additive central nervous system (CNS) depressant effect. The co-ingestion of zopiclone with alcohol (ethanol) is strongly advised against or formally prohibited in regulatory documentation due to the significant risk of potentiating these effects, including severe sedation and respiratory depression. Other CNS depressants, such as opioids, benzodiazepines, and antipsychotics, are likewise noted for their additive effects.

For administrative timing, official labeling advises against taking the tablet with or immediately after a high-fat or heavy meal, as this is documented to delay the time to peak concentration ( T max). Furthermore, regulatory documents specify that patients with severe hepatic impairment exhibit a documented increase in systemic exposure, an important population-specific interaction constraint.

Mechanism of Action

Hypnor's active metabolite, M1, functions by selectively modulating the activity of the Wnt/beta-catenin signaling pathway. This selective activity reduces sclerostin binding to the LRP5/6 receptor complex on osteoblasts, which subsequently results in increased osteoblast differentiation and proliferation. This intracellular cascade enhances the production of osteoid matrix and the subsequent mineralization process, representing the primary anabolic component of the mechanism.

Additionally, M1 suppresses the expression of RANKL in osteocytes. This action decreases osteoclast maturation and activity, providing an anti-catabolic effect. The coupled physiological result of increased osteoblast activity and decreased osteoclast activity is positive bone remodeling and an increase in bone mineral density. The overall actions shift the skeletal physiological balance toward net bone gain.

Dosage and Administration Information

How Hypnor is Used: Official Administration Guidelines

Hypnor, containing the active ingredient zopiclone, is intended for oral administration as a single-ingredient tablet. Its usage is subject to established clinical parameters to ensure adherence to labeled dosing and administration.


Standard Labeled Use

The medication is to be taken as a single dose once nightly, immediately before retiring for the night. The established standard dose for adults is 7.5 mg. It is specified that the total dose must not exceed 7.5 mg in a 24-hour period, and the medication must not be re-administered during the same night.

Administration involves swallowing the tablet whole with water; the product labeling advises against crushing, chewing, or sucking the tablet, as its intended release is designed for intact ingestion.


Duration and Population Adjustments

The course of treatment with zopiclone is intended to be for the shortest duration possible, ranging from a few days up to two weeks in typical scenarios. The total treatment duration, including any necessary period for gradually reducing the dose (tapering), must not exceed four weeks.

Specific populations require a mandatory dose reduction upon initiation: treatment for older adults (geriatric) and patients with hepatic or renal impairment should begin with a reduced dose of 3.75 mg. This reduced starting dose may be adjusted to the standard 7.5 mg only if clinically required and appropriate for the patient's condition. The medication is not recommended for use in adolescents and children under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hypnor (Zopiclone)

Evidence for Use in Short-Term Insomnia Management

The primary research base for zopiclone was studied for short-term insomnia, a condition where symptoms may vary in intensity. Research examining these temporary physiological imbalances primarily consists of Randomized Controlled Trials (RCTs). These short-term trials often compared the medicine to an inactive substance (placebo) or to other similar sleep aids.

These studies monitored specific outcomes describing episodic or acute changes related to sleep. Researchers tracked both objective sleep metrics, using specialized lab tests like polysomnography (PSG) to measure things like the actual time subjects took to fall into a deep, persistent sleep and the duration of wakefulness after sleep onset. They also looked at patient-reported outcomes describing perceived discomfort, such as how long patients felt it took them to fall asleep and their subjective sleep quality.

Findings describe patterns observed in the studies over the short follow-up periods. When compared to a placebo, studies explored data show patterns related to sleep onset latency (time to fall asleep) and total sleep time (TST). However, the data show that follow-up duration was short-term, typically covering periods of use up to six weeks. Research describes measurements collected during the study period and provides context, but research does not determine whether an individual will respond similarly.


Research on Specific Populations: Older Adults

Zopiclone was evaluated in studies focusing specifically on older adults (typically those aged 60 and older), as this demographic frequently experiences sleep difficulties. Research examined how symptoms evolved in these observed populations.

These trials tracked the same core sleep metrics (time to fall asleep and total sleep time) using both laboratory and patient-reported methods. Data show patterns related to measured sleep outcomes in older adults, though findings were mixed or varied across studies. Furthermore, follow-up durations were limited for many studies focusing on episodes where symptoms become more noticeable in this group, and sample sizes were modest.


Evaluating Data on Long-Term Outcomes and Follow-up

The evidence landscape for zopiclone is characterized by follow-up durations that were limited. The short-term RCTs that form the foundation of the evidence typically studies monitored observations over defined time intervals lasting no more than four to six weeks.

There is limited information for long-term outcomes that may result from continuous use extending beyond this period. Studies exploring short-term symptom changes do not fully characterize the durability of short-term findings or the patterns of use in a daily-life setting over many months. Observational settings evaluating daily-life functioning over longer periods are available, but they are not the same as the controlled setting of an RCT.


Evidence Gaps and Areas of Uncertainty

A key limitation is the fact that the long-term effects are not fully established and there is a general absence of controlled, long-term evidence. The majority of findings describe group patterns, not personal outcomes, and research provides insight into short-term changes only.

Another limitation is that evidence quality varies across studies. Comparative evidence is lacking or inconclusive in many head-to-head trials. Additionally, many studies rely heavily on patient-reported outcomes describing perceived discomfort, which may differ from the objective measurements recorded in a sleep lab. This makes it difficult to draw broad, certain conclusions about its use across all conditions where symptoms may vary in intensity.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE): Insomnia management guidelines
  2. Summary of Product Characteristics (SPC) - Zopiclone (e.g., European Medicines Agency/MHRA equivalent)

Frequently Asked Questions (FAQ)

Common questions about Hypnor (FAQ)

Q: How quickly does Hypnor start working?

A: Official information regarding the medicine indicates that the onset of action is generally rapid. Regulatory documents describe the onset of action as generally rapid, with effects often reported to begin within about 30 minutes after taking the tablet.


Q: Can I use Hypnor if I have kidney problems?

A: Regulatory documents describe that treatment initiation for patients with impaired kidney function often involves a reduced dose. While drug accumulation has not been widely detected, official information notes that a lower starting dose is described for this population. Official documents list specific contraindications related to liver function, not kidney function.


Q: Are the side effects of Hypnor usually mild or severe?

A: Reported effects are classified by frequency in official documents. Common effects, such as a bitter taste and daytime sleepiness, are frequently reported and often temporary. However, the medicine is also associated with rare, serious risks like severe allergic reactions or performing complex sleep behaviors while not fully awake.


Q: Is Hypnor considered an addictive drug?

A: Official patient information notes that there is a risk of developing physical and psychological dependence and a withdrawal syndrome if the drug is taken for longer than the recommended short duration. Regulatory documents specify that the course of treatment is intended to be for the shortest possible duration, which is intended to reduce this specific risk.


Q: Is it common to feel tired the morning after taking Hypnor?

A: Yes, official regulatory documentation classifies somnolence (daytime sleepiness) as a common side effect of the medicine. The potential for next-day effects is noted to be greater if the prescribed dose is exceeded or in older adults.


Q: Does Hypnor affect the way other medicines like blood thinners work?

A: Hypnor is metabolized (broken down) in the body through a specific enzyme system, CYP3A4. If other medicines, including certain blood thinners, significantly affect this enzyme system, it could change the amount of Hypnor in the body. Official labeling contains detailed information regarding co-administration.


Q: Does Hypnor cause weight gain?

A: Official regulatory documents classifying the known adverse effects of this medicine do not list weight gain or weight loss as a reported side effect.


Q: Can women who are pregnant or breastfeeding use Hypnor?

A: The use of this medicine is generally not recommended during pregnancy and while breastfeeding. Official labeling documents potential risks to the infant or fetus, including breathing difficulties or muscle weakness, that have been observed.


Q: Is there a possibility of a rebound effect when stopping Hypnor?

A: Regulatory documents describe a possibility of 'rebound insomnia' upon withdrawal of treatment. This is a temporary syndrome where the sleep symptoms that led to treatment recur in a more intense form. The risk is noted to be higher following abrupt discontinuation, particularly after prolonged use.


Q: What is the risk of having a serious interaction with other medicines?

A: The risk of a serious interaction is specifically highlighted in official documents when Hypnor is combined with substances that also cause central nervous system (CNS) depression. Combining these, such as alcohol or other Central Nervous System (CNS) depressants, is documented to significantly increase the risk of severe sedation, respiratory depression, or other serious outcomes.


Q: Why do official documents describe the benefits of Hypnor in a specific way?

A: Official documents must strictly reflect the evidence gathered from clinical studies and regulatory approval processes. This limits the description of benefits to neutral statements about measured outcomes, such as reducing the time it takes to fall asleep. The language used is consistently neutral to comply with legal and scientific standards.


Q: What kind of research has been done on Hypnor?

A: The primary research basis for the medicine consists of Randomized Controlled Trials (RCTs). These short-term studies monitored specific sleep outcomes in adults and specific patient groups, such as older adults, comparing the drug to an inactive substance (placebo) or similar sleep aids.


Q: What if I forget to take Hypnor?

A: Official patient information describes that if a dose is forgotten by your regular bedtime, the guidance is to skip the missed dose entirely. The labeling specifies that the user should not take two doses, but should take the next dose at the usual time the following night.


Q: Are there any common over-the-counter medicines that interact with Hypnor?

A: Yes, regulatory documents warn that Hypnor's sedative effects can be increased by other central nervous system (CNS) depressants. This can include certain over-the-counter medicines, such as some antihistamines, which are noted to have CNS-depressant properties.


Q: Are there any long-term effects associated with Hypnor use?

A: Official labeling documents that the evidence base is primarily from short-term studies, typically lasting up to four to six weeks. Risks explicitly associated with continuous use beyond this period are dependence, tolerance, and withdrawal effects upon cessation. Evidence for its safety and efficacy is limited for use extending beyond this short-term period.


Q: Is Hypnor related to any class of drugs that cause dependency?

A: Hypnor is classified as a 'Z-drug,' which is a non-benzodiazepine hypnotic agent and is chemically distinct from benzodiazepines. However, because it is a central nervous system depressant, it is officially classified as a prescription medicine with a potential for abuse and dependence.


Q: What are the symptoms of an allergic reaction to Hypnor?

A: Signs of a severe hypersensitivity or allergic reaction are documented to include a rash, difficulties with swallowing or breathing, and swelling of the lips, face, throat, or tongue. Official guidance notes that these symptoms require immediate professional assessment.


Q: How does the mechanism of Hypnor compare to non-prescription remedies?

A: Hypnor is a prescription hypnotic that works by binding to specific receptors in the central nervous system, enhancing the effects of the natural calming chemical, GABA, to promote sleep. This is a targeted pharmacological action that is chemically distinct from most herbal or over-the-counter remedies.


Q: Is it normal to have vivid dreams while taking Hypnor?

A: Regulatory documents list nightmares as an uncommon side effect of the medicine. Other psychiatric effects, including vivid dreams and hallucinations, are also documented to occur among a small percentage of users.


Q: Does Hypnor interact with common supplements like melatonin or multivitamins?

A: Official drug documents advise caution with all co-administered supplements and medicines. The herbal product St. John's Wort is specifically noted as a substance that may reduce Hypnor's effectiveness. Caution is generally advised when combining Hypnor with any supplement that may also cause sleepiness or drowsiness.


Q: Is Hypnor suitable for long-term use?

A: Regulatory documents specify that the course of treatment is intended to be for the shortest duration possible. The total treatment duration, including any period for gradually stopping the medicine, should not exceed four weeks. Evidence for its safety and efficacy is limited for use extending beyond this short-term period.


Q: What makes Hypnor different from an anxiolytic medicine?

A: Hypnor is officially classified as a hypnotic agent, meaning its primary, intended, and labeled function is to promote and maintain sleep. Its structure and official classification in regulatory documents support its intended use as a sleep promoter, differentiating its primary function from that of an anxiolytic (anti-anxiety) medicine.


Q: What is the recommended age range for taking Hypnor?

A: The medicine is intended for use in adults over the age of 18 years. Official documents state it is not to be used in children and adolescents under 18 years. Additionally, older adults (aged 65 and over) are a specific population group for which a lower starting dose is described in official documents.


Q: Does the time of day matter when taking Hypnor?

A: Yes, official administration guidelines consistently specify that the medication must be taken as a single dose once nightly. It must be taken immediately before attempting to sleep for the night to ensure the user is in bed for the duration of the effect and to minimize next-day residual sleepiness.


Q: What should I do if a side effect seems concerning but not severe?

A: Official patient information often describes that concerning side effects that are not severe are generally managed through consultation with a healthcare provider for guidance. Any signs of a severe allergic reaction or complex sleep behaviors, however, require immediate professional assessment.


Q: Does Hypnor require any special monitoring or tests?

A: Official information does not mandate routine monitoring for all users of the medication. However, in specific populations, such as those with existing liver impairment, some drug information sources describe that laboratory testing should be considered prior to and during treatment.


Q: How does Hypnor relate to brain chemistry according to official sources?

A: According to official information, the drug's primary function is to influence the gamma-aminobutyric acid (GABA) system in the brain. Hypnor binds to the GABAA receptor, which enhances the natural calming effect of GABA, promoting decreased brain activity and inducing sleepiness.


Q: Is there a generic version of Hypnor available?

A: Hypnor is a brand name for the active ingredient, zopiclone. Since the generic medication zopiclone is widely available, an individual can typically access a non-branded alternative to the Hypnor brand.

How should Hypnor be stored and disposed of?

How to Store and Dispose of Hypnor (Zopiclone)

The storage and disposal of Hypnor (zopiclone) oral tablets must follow official regulatory requirements to ensure product stability and safety.

Storage Requirements

Hypnor must be stored at or below 30 C and kept in a dry environment, protected from both light and heat. To maintain stability, the tablets must remain in the original container and stay within the blister packaging until the time of use. The medicine must not be used after the expiration date printed on the packaging. As a potent prescription medication, Hypnor must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Hypnor must be disposed of in accordance with local requirements. Official regulatory guidance advises against throwing the medicine away via wastewater or household waste. Instead, consumers are directed to utilize authorized drug take-back programs or collection points for safe and environmentally compliant disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hypnor found in:

A-Z Index: